ArticleScientific reports2021
Prevalence of different comorbidities in chronic obstructive pulmonary disease among Shahrekord PERSIAN cohort study in southwest Iran.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Association between hypertension and impaired lung function among adults: A systematic review and meta-analysis.PloS one · 2026Pooled it
- Negligible effect of vitamin D supplementation on exacerbation in patients with chronic obstructive pulmonary disease: meta-analysis.Biochemia medica · 2023Pooled it
- The prevalence of metabolic syndrome in chronic obstructive pulmonary disease: A systematic review and meta-analysis.Chronic respiratory diseasePooled it
- Bidirectional Clinical Interactions among Exacerbations and Comorbidities in COPD: A Narrative Review.Seminars in respiratory and critical care medicine · 2026Review
- 25-Hydroxyvitamin D Deficiency Elevates the Risk of COPD Incidence and Mortality: A Large Population-Based Prospective Cohort Study.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2026Article
- Exploring Network Relationships Between Health Status and Frailty in COPD Patients with Multimorbidity: A Cross-Sectional Study.Journal of multidisciplinary healthcare · 2026Article
- Chronic Obstructive Pulmonary Disease and Multimorbidity: Insights from a National Claims Administrative Database.International journal of chronic obstructive pulmonary disease · 2026Article
- Comorbidities and Cause of Death in COPD Patients Compared to Non-COPD Controls: An 8-year Observational Retrospective Healthcare Claims Database Cohort Study.International journal of chronic obstructive pulmonary disease · 2025Observational
- Prevalence, Risk Factors of Preserved Ratio Impaired Spirometry in adult in plateau: A Cross-Sectional Study.PloS one · 2025Article
- Sex disparity in the burden of NCDs and its four main subgroups in Iran 1990-2019: a systematic analysis from the global burden of disease study 2019.Journal of diabetes and metabolic disorders · 2024Article
- Living with COPD and its psychological effects on participating in community-based physical activity in Brazil: a qualitative study. Findings from the Breathe Well group.NPJ primary care respiratory medicine · 2024Article
- Delineating excess comorbidities in idiopathic pulmonary fibrosis: an observational study.Respiratory research · 2024Observational
- Proportions and risk factors of chronic obstructive pulmonary disease and preserved ratio impaired spirometry, and association with small airway disease, in the positive screening older population from China: a cross-sectional study.BMC pulmonary medicine · 2024Article
- Associations Between Physical Activity and Preserved Ratio Impaired Spirometry: A Cross-Sectional NHANES Study.International journal of chronic obstructive pulmonary disease · 2024Article
- The effect of dignity therapy on anxiety and depression in patients with chronic obstructive pulmonary disease: A randomized clinical trial.Journal of education and health promotion · 2024Article
- Elucidating the Link: Chronic Obstructive Pulmonary Disease and the Complex Interplay of Gastroesophageal Reflux Disease and Reflux-Related Complications.Medicina (Kaunas, Lithuania) · 2023Article
- Review
- Profile and preliminary results of Iranian sub cohort chronic obstructive pulmonary disease (COPD) in Shahrekord PERSIAN cohort in southwest Iran.BMC pulmonary medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comorbidities are common in chronic obstructive pulmonary disease (COPD) patients. This study was conducted to determine the prevalence of common comorbidities in patients with COPD compared with people without COPD. This cross-sectional, population-based study was performed on 6961 adults aged 35-70 years enrolled in the Shahrekord PERSIAN cohort study. Data (demographic and clinical characteristics, comorbidities, anthropometric and blood pressure measurements, laboratory, and spirometry tests) collection was performed according to the cohort protocol from 2015 to 2019. In the present study, 215 (3.1%) patients were diagnosed with COPD and 1753 (25.18%) ones with restrictive lung patterns. The mean age of COPD patients was 52.5 ± 9.76 years. 55.8% of patients were male, 17.7% were current smokers and 12.1% had a history of smoking or were former smokers. 5.6% of patients had no comorbidity and 94.5% had at least one comorbidity. The most common comorbidities in COPD patients were dyslipidemia (70.2%), hypertension (30.2%), metabolic syndrome (22.8%), and diabetes (16.7%). The most common comorbidities in individuals with a restrictive spirometry pattern were dyslipidemia (68.9%), metabolic syndrome (27.2%), hypertension (26.1%), depression (17.6%), and fatty liver (15.5%). The logistic regression analysis with 95% confidence interval (95%CI) of odds ratio (OR) showed that comorbidities of chronic lung diseases (OR = 2.12, 95% CI 1.30-3.44), diabetes (OR = 1.54, 95%CI 1.03-2.29), cardiovascular disease (OR = 1.52, 95%CI 1.17-2.43), and hypertension (OR = 1.4, 95%CI 1.02-1.99) were more likely to occur in COPD patients than in healthy individuals. Knowing these prevalence rates and related information provides new insights on comorbidities to reduce disease burden and develop preventive interventions and to regulate health care resources to meet the needs of patients in primary health care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.